Welcome to our dedicated page for Xortx Therapeutics news (Ticker: XRTX), a resource for investors and traders seeking the latest updates and insights on Xortx Therapeutics stock.
XORTX Therapeutics Inc. (XRTX) news covers a late-stage clinical pharmaceutical company focused on developing therapies for gout, progressive kidney disease, and related disorders driven by aberrant purine metabolism and elevated uric acid. Company updates emphasize programs that target xanthine oxidase, a key enzyme in uric acid production, and explore how genetic and molecular insights can inform treatment strategies.
Readers of this page can follow announcements on XORTX’s lead XRx-026 gout program and its proprietary oxypurinol formulation XORLO™, including regulatory interactions, Investigational New Drug (IND) preparation, clinical trial plans, and progress toward potential New Drug Application (NDA) submissions. News also highlights development of XRx-008 for autosomal dominant polycystic kidney disease (ADPKD), XRx-101 for acute kidney and organ injury associated with respiratory virus infections, and XRx-225 for Type 2 diabetic nephropathy.
In addition to clinical and scientific milestones, XRTX news items report on financing activities such as registered direct offerings, at-the-market issuances, and private placements, as well as Nasdaq listing updates, including minimum bid price deficiency notices and compliance timelines. Corporate developments, including board changes, strategic planning, and the planned acquisition of the VB4-P5 renal anti-fibrotic program from Vectus Biosystems Limited, are also covered.
This news feed brings together scientific findings on xanthine oxidase and uric acid, regulatory and clinical progress in gout and kidney disease programs, and capital markets disclosures. Investors and observers can use it to monitor how XORTX’s research, pipeline evolution, and financing decisions shape the company’s efforts in gout and kidney-related therapeutics.
XORTX Therapeutics Inc. announced the receipt of a no objection letter from Health Canada for its XRX-OXY-101 clinical bridging pharmacokinetics study. The study aims to identify the optimal formulation for oxypurinol and assess food effect, safety, and pharmacokinetics. This information is critical for advancing toward a phase 3 trial in Autosomal Dominant Polycystic Kidney Disease (ADPKD). Dr. Allen Davidoff emphasized that this milestone accelerates the development of the XRx-008 program towards potential marketing approvals for treating progressive kidney disease.
XORTX Therapeutics Inc. has announced the granting of a patent for its proprietary formulations in treating Autosomal Dominant Polycystic Kidney Disease (ADPKD). The patent, titled 'Formulations of Xanthine Oxidase Inhibitors,' provides 20 years of protection for XRx-008, aimed at addressing the unmet medical needs in progressive kidney diseases. Approximately 3 million individuals globally suffer from ADPKD. This patent strengthens XORTX's intellectual property portfolio in the U.S., paving the way for expanded clinical trials and partnership opportunities.
XORTX Therapeutics Inc. has filed an investigational new drug (IND) application with the FDA for its XRx-008 program targeting autosomal dominant polycystic kidney disease (ADPKD). This IND supports the initiation of clinical trials for a combination of uric acid-lowering agents aimed at slowing disease progression. Currently, few treatment options exist for ADPKD, with only one approved drug, Tolvaptan. The company aims to advance XRx-008 to provide better outcomes for patients, as recent evidence indicates that high uric acid levels are a risk factor for kidney function decline.
XORTX Therapeutics has submitted a Patent Cooperation Treaty application for a patent titled “Compositions and Methods for Enhancing Anti-Viral Therapies”. This patent focuses on addressing purine metabolism and hyperuricemia, particularly in individuals at risk for severe COVID-19 outcomes, including those with obesity and chronic kidney disease. The submission is based on retrospective clinical data suggesting the potential for uric acid-lowering agents to inhibit SARS-CoV-2 replication. The company clarifies that it does not claim to cure or contain COVID-19.
XORTX Therapeutics has submitted a clinical trial application for its XRX-OXY-101 bridging pharmacokinetics study to Health Canada. This study aims to evaluate the optimal formulation for circulating oxypurinol concentrations, assess food effects on bioavailability, and understand safety and pharmacokinetics. The results will inform future oral dosing for the planned phase 3 trial targeting Autosomal Dominant Polycystic Kidney Disease (ADPKD). The outcomes will also support marketing submissions to the FDA and EMA.
XORTX Therapeutics Inc. (NASDAQ: XRTX) reported significant achievements in 2021 and outlined strategic goals for 2022. Key highlights include raising $20 million through equity financings, advancement of XRx-008 for ADPKD, and XRx-101 targeting acute kidney injury from COVID-19. The company secured several patents and engaged in partnerships with notable institutions like Mount Sinai Hospital. Upcoming plans include initiating clinical trials and seeking orphan drug designation to enhance its product pipeline aimed at improving patient outcomes in kidney diseases.
XORTX Therapeutics has appointed Dr. David MacDonald as the new Chief Technology Officer (CTO), enhancing its leadership with over 30 years of drug development expertise. Dr. MacDonald previously held senior roles at MSI Methylation Sciences and Active Pass Pharmaceutics, demonstrating a solid track record in R&D and clinical development. The company also issued 127,500 stock options priced at $2.54 CAD, set to expire in five years. XORTX focuses on developing therapies for progressive kidney diseases, with clinical products aimed at ADPKD and acute organ injury related to COVID-19.
XORTX Therapeutics Inc. (NASDAQ: XRTX) announced its participation in the H.C. Wainwright BioConnect 2022 Virtual Conference from January 10-13, 2022. Dr. Allen Davidoff, CEO, will provide a company progress update and outline planned activities for 2022. A pre-recorded presentation will be available via a provided link. Dr. Davidoff expressed enthusiasm about the opportunity to engage with global investors and pharmaceutical partners during this busy week of meetings associated with the JP Morgan virtual conference.
XORTX Therapeutics Inc. (NASDAQ: XRTX) announced the results of its 2021 Annual Meeting of Shareholders, where approximately 38% of shares were voted. All resolutions passed almost unanimously, including the election of six directors and the re-appointment of Smythe LLP as auditors. The company also approved a 10% rolling stock option plan. Following Raymond Pratt's appointment, 30,000 stock options were granted at $2.54 CAD, along with 56,495 options to independent directors. XORTX is developing therapies for progressive kidney diseases, including XRx-008 for ADPKD and XRx-101 for COVID-19-related kidney injury.
XORTX Therapeutics announced the filing of a provisional patent related to polycystic kidney disease (PKD), focusing on a new mechanism of injury tied to aberrant purine metabolism. This patent covers methods for diagnosing and treating PKD by addressing xanthine oxidase expression and uric acid levels. CEO Dr. Allen Davidoff highlighted the importance of these findings, which aim to expand the company's patent portfolio and enhance product development opportunities. The lead program, XRx-008, targets progressing kidney disease due to autosomal dominant PKD.